After blocking the interaction between VISG4 and CD8 + T cells with VSIG4 antibody, it can relieve the functional inhibition of T cells, polarize M2 macrophages into M1 macrophages, stimulate the proliferation of CD8 + T cells, and thus inhibit tumor (Huang et al., 2019a, p. 4). The gene discussed is CD8A; the disease is neoplasm.